Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile BARD1 Y180fs BARD1 loss
Therapy Irinotecan + Talazoparib
Indication/Tumor Type neuroblastoma
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
BARD1 Y180fs BARD1 loss neuroblastoma predicted - sensitive Irinotecan + Talazoparib Case Reports/Case Series Actionable In a clinical case study, treatment with the combination of Talzenna (talazoparib) and Camptosar (irinotecan) resulted in a complete response in a pediatric patient with high-risk relapsed/refractory neuroblastoma harboring germline BARD1 Y180fs and somatic Bard1 loss (PMID: 39141861). 39141861
PubMed Id Reference Title Details
(39141861) Response to PARP Inhibition in BARD1-Mutated Refractory Neuroblastoma. Full reference...